scispace - formally typeset
P

P. Tammaro

Researcher at University of Naples Federico II

Publications -  27
Citations -  612

P. Tammaro is an academic researcher from University of Naples Federico II. The author has contributed to research in topics: Blood pressure & Telmisartan. The author has an hindex of 9, co-authored 27 publications receiving 598 citations.

Papers
More filters
Journal ArticleDOI

Cardiac abnormalities in young women with anorexia nervosa.

TL;DR: Anorexia nervosa caused demonstrable abnormalities of mitral valve motion and reduced left ventricular mass and filling associated with systolic dysfunction.
Journal ArticleDOI

Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance

TL;DR: Results clearly indicate that early abnormalities of cardiac structure and function are observed not only in patients with NIDDM, but also in those with impaired glucose tolerance, independent of the confounding role of myocardial ischemia, body weight, and blood pressure.
Journal ArticleDOI

Three-Dimensional Echocardiographic and Magnetic Resonance Assessment of the Effect of Telmisartan Compared With Carvedilol on Left Ventricular Mass A Multicenter, Randomized, Longitudinal Study

TL;DR: The superior LVM regression with tel Misartan versus carvedilol suggests telmisartan has a mechanism that may be beyond that of lowering BP in hypertensive patients.
Journal ArticleDOI

Blood pressure and cardiac morphology in young children of hypertensive subjects.

TL;DR: Early cardiac alterations and a tendency for effort hypertension in children of hypertensives are confirmed and could be explained by effort systolic overload or by a common response to an increased adrenergic stimulus.
Journal ArticleDOI

Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study.

TL;DR: Adult patients with mild-to-moderate hypertension and an optimal acoustic window by two-dimensional echocardiography were randomised at baseline to 12 months' double-blind, once-daily treatment with telmisartan, an angiotensin II receptor blocker, and tolerability and effects on left ventricular mass index were compared with HCTZ.